表紙
市場調査レポート

肺癌診断製品:パイプライン分析

Lung Cancer - Pipeline Review, 2015

発行 GlobalData 商品コード 342288
出版日 ページ情報 英文 285 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
肺癌診断製品:パイプライン分析 Lung Cancer - Pipeline Review, 2015
出版日: 2015年10月01日 ページ情報: 英文 285 Pages
概要

当レポートでは、世界各国の企業・医療機関などで開発中の、肺癌診断の関連製品 (診断装置・試薬など) のパイプライン製品情報について分析し、治験/製品開発の全体的な進行状況や、段階別・分野別・地域別の詳細動向、企業別・製品別の詳細情報 (治験の進行段階、開始/終了時期、認証見通しなど)、昨今の製品開発の動き・業界動向などを盛り込んでお届けいたします。

第1章 目次

第2章 イントロダクション

  • 肺癌診断製品 (診断装置・試薬など) の概要

第3章 開発中の製品

  • パイプライン製品:開発段階別
  • パイプライン製品:地域別
  • パイプライン製品:規制経路別
  • パイプライン製品:認証時期別 (推定)
  • 現在進行中の治験

第4章 肺癌診断製品:開発中のパイプライン製品 (企業別)

  • 肺癌診断製品の開発企業:パイプライン製品 (開発段階別)
  • 肺癌診断製品:開発段階別のパイプライン製品の一覧

第5章 肺癌診断製品の開発企業・製品の概要

  • A&G Pharmaceutical, Inc.
  • Abbott Diagnostics
  • Abcodia Ltd.
  • Aberystwyth University
  • Advanced Marker Discovery, S.L.
  • Advpharma Inc.
  • Almac Diagnostics Limited
  • Armune BioScience, Inc.
  • Aurelium BioPharma Inc. (Inactive)
  • Biocept, Inc.
  • Biodesix Inc.
  • BioMark Diagnostics Inc.
  • BioMark Technologies Inc.
  • BioMarker Strategies, LLC
  • Biomoda, Inc. (Inactive)
  • BioNTech AG
  • BioSystems International
  • BioTime, Inc.
  • Boise State University
  • Cancer Research Technology Limited
  • Cangen Biotechnologies, Inc.
  • Celera Corporation
  • Cellanyx Diagnostics, Inc.
  • CellMax Life
  • CeMines, Inc.
  • Cepheid
  • Ceres Nanosciences, Inc.
  • Cernostics Inc.
  • ChemImage Corporation
  • Chronix Biomedical, Inc.
  • Clarient, Inc.
  • Courtagen Life Sciences, Inc.
  • Dako A/S
  • Dartmouth College
  • DiagnoCure Inc.
  • EDP Biotech
  • Emory University
  • Epigenomics AG
  • Eventus Diagnostics, Inc.
  • Exact Sciences Corporation
  • Exiqon A/S
  • Exosomics Siena SpA
  • Fina Biotech
  • Fluxion Biosciences, Inc.
  • Forschungszentrum Borstel
  • Gene Express, Inc.
  • GeneCentric Diagnostics, Inc.
  • Genentech, Inc.
  • GenomicTree, Inc.
  • GILUPI Nanomedizin
  • Global Discovery Biosciences
  • GlycoZym
  • HTG Molecular Diagnostics, Inc.
  • ImmunoCellular Therapeutics, Ltd.
  • Insight Genetics, Inc.
  • Institut National de la Sante et de la Recherche Medicale
  • InterGenetics Incorporated
  • IV Diagnostics, Inc.
  • Laboratorios SALVAT S.A.
  • Louisville Bioscience, Inc.
  • Mayo Clinic
  • MDNA Life Sciences, Inc.
  • MDxHealth SA
  • Medical Prognosis Institute A/S
  • MEDITE Cancer Diagnostics, Inc.
  • Memory Dx, LLC
  • Metabolon, Inc.
  • Metanomics Health GmbH
  • MetaStat, Inc.
  • Milagen, Inc.
  • MolecularMD, Corp.
  • Nanopore Diagnostics, LLC
  • Neogenix Oncology, Inc.
  • NEOMICS Co., Ltd.
  • Novel Bio-spectrum Technologies, Inc.
  • Nuvera Biosciences, Inc.
  • Oncolome Diagnostics Inc.
  • Onconome, Inc.
  • On-Q-ity, Inc. (Inactive)
  • OPKO Health, Inc.
  • Orion Genomics LLC
  • OTraces Inc.
  • Oxford Gene Technology Limited
  • PeriRx LLC
  • PleX Diagnostics
  • Precision Biologics, Inc.
  • PreMD Inc.
  • Proplex Technologies, Llc
  • Proteome Sciences Plc
  • Proteomika
  • Quest Diagnostics Incorporated
  • RCP Diagnostics, LLC (Inactive)
  • RiboMed Biotechnologies, Inc.
  • Roche Diagnostics International Ltd.
  • Rosetta Genomics, Ltd.
  • Roswell Park Cancer Institute
  • Siemens Healthcare Diagnostics Inc.
  • Sienna Cancer Diagnostics Ltd
  • Sividon Diagnostics GmbH
  • SomaLogic, Inc.
  • Southern Illinois University Carbondale
  • Syndax Pharmaceuticals, Inc.
  • The Wistar Institute
  • Todos Medical
  • Transgene SA
  • Trinity College Dublin
  • University of Chicago
  • University of Colorado
  • University of South Florida
  • University of Strathclyde
  • US Biomarkers, Inc.
  • Ventana Medical Systems, Inc.
  • Veracyte, Inc.
  • Vigilant Biosciences, Inc.
  • Viomics Inc.
  • VisionGate, Inc.
  • Vitatex Inc.
  • VolitionRX Ltd.
  • XEPTAGEN SpA
  • Zetiq Technologies Ltd.

第6章 肺癌診断製品:昨今の市場動向

第7章 付録

図表一覧

目次
Product Code: GDME0071EPD

GlobalData's Medical Devices sector report, "Lung Cancer - Pipeline Review, 2015" provides an overview of Lung Cancer diagnostic tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Lung Cancer diagnostic tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Lung Cancer diagnostic tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Lung Cancer diagnostic tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Lung Cancer diagnostic tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Lung Cancer Overview

3. Products under Development

  • 3.1. Lung Cancer - Pipeline Products by Stage of Development
  • 3.2. Lung Cancer - Pipeline Products by Territory
  • 3.3. Lung Cancer - Pipeline Products by Regulatory Path
  • 3.4. Lung Cancer - Pipeline Products by Estimated Approval Date
  • 3.5. Lung Cancer - Ongoing Clinical Trials

4. Lung Cancer - Pipeline Products under Development by Companies

  • 4.1. Lung Cancer Companies - Pipeline Products by Stage of Development
  • 4.2. Lung Cancer - Pipeline Products by Stage of Development

5. Lung Cancer Companies and Product Overview

  • 5.1. A&G Pharmaceutical, Inc. Company Overview
  • 5.2. Abbott Diagnostics Company Overview
  • 5.3. Abcodia Ltd. Company Overview
  • 5.4. Aberystwyth University Company Overview
  • 5.5. Advanced Marker Discovery, S.L. Company Overview
  • 5.6. Advpharma Inc. Company Overview
  • 5.7. Almac Diagnostics Limited Company Overview
  • 5.8. Armune BioScience, Inc. Company Overview
  • 5.9. Aurelium BioPharma Inc. (Inactive) Company Overview
  • 5.10. Biocept, Inc. Company Overview
  • 5.11. Biodesix Inc. Company Overview
  • 5.12. BioMark Diagnostics Inc. Company Overview
  • 5.13. BioMark Technologies Inc. Company Overview
  • 5.14. BioMarker Strategies, LLC Company Overview
  • 5.15. Biomoda, Inc. (Inactive) Company Overview
  • 5.16. BioNTech AG Company Overview
  • 5.17. BioSystems International Company Overview
  • 5.18. BioTime, Inc. Company Overview
  • 5.19. Boise State University Company Overview
  • 5.20. Cancer Research Technology Limited Company Overview
  • 5.21. Cangen Biotechnologies, Inc. Company Overview
  • 5.22. Celera Corporation Company Overview
  • 5.23. Cellanyx Diagnostics, Inc. Company Overview
  • 5.24. CellMax Life Company Overview
  • 5.25. CeMines, Inc. Company Overview
  • 5.26. Cepheid Company Overview
  • 5.27. Ceres Nanosciences, Inc. Company Overview
  • 5.28. Cernostics Inc. Company Overview
  • 5.29. ChemImage Corporation Company Overview
  • 5.30. Chronix Biomedical, Inc. Company Overview
  • 5.31. Clarient, Inc. Company Overview
  • 5.32. Courtagen Life Sciences, Inc. Company Overview
  • 5.33. Dako A/S Company Overview
  • 5.34. Dartmouth College Company Overview
  • 5.35. DiagnoCure Inc. Company Overview
  • 5.36. EDP Biotech Corporation Company Overview
  • 5.37. Emory University Company Overview
  • 5.38. Epigenomics AG Company Overview
  • 5.39. Eventus Diagnostics, Inc. Company Overview
  • 5.40. Exact Sciences Corporation Company Overview
  • 5.41. Exiqon A/S Company Overview
  • 5.42. Exosomics Siena SpA Company Overview
  • 5.43. Fina Biotech Company Overview
  • 5.44. Fluxion Biosciences, Inc. Company Overview
  • 5.45. Forschungszentrum Borstel Company Overview
  • 5.46. Gene Express, Inc. Company Overview
  • 5.47. GeneCentric Diagnostics, Inc. Company Overview
  • 5.48. Genentech, Inc. Company Overview
  • 5.49. GenomicTree, Inc. Company Overview
  • 5.50. GILUPI Nanomedizin Company Overview
  • 5.51. Global Discovery Biosciences Company Overview
  • 5.52. GlycoZym Company Overview
  • 5.53. HTG Molecular Diagnostics, Inc. Company Overview
  • 5.54. ImmunoCellular Therapeutics, Ltd. Company Overview
  • 5.55. Insight Genetics, Inc. Company Overview
  • 5.56. Institut National de la Sante et de la Recherche Medicale Company Overview
  • 5.57. InterGenetics Incorporated Company Overview
  • 5.58. IV Diagnostics, Inc. Company Overview
  • 5.59. Laboratorios SALVAT S.A. Company Overview
  • 5.60. Louisville Bioscience, Inc. Company Overview
  • 5.61. Mayo Clinic Company Overview
  • 5.62. MDNA Life Sciences, Inc. Company Overview
  • 5.63. MDxHealth SA Company Overview
  • 5.64. Medical Prognosis Institute A/S Company Overview
  • 5.65. MEDITE Cancer Diagnostics, Inc. Company Overview
  • 5.66. Memory Dx, LLC Company Overview
  • 5.67. Metabolon, Inc. Company Overview
  • 5.68. Metanomics Health GmbH Company Overview
  • 5.69. MetaStat, Inc. Company Overview
  • 5.70. Milagen, Inc. Company Overview
  • 5.71. MolecularMD, Corp. Company Overview
  • 5.72. Nanopore Diagnostics, LLC Company Overview
  • 5.73. Neogenix Oncology, Inc. Company Overview
  • 5.74. NEOMICS Co., Ltd. Company Overview
  • 5.75. Novel Bio-spectrum Technologies, Inc. Company Overview
  • 5.76. Nuvera Biosciences, Inc. Company Overview
  • 5.77. Oncolome Diagnostics Inc. Company Overview
  • 5.78. Onconome, Inc. Company Overview
  • 5.79. On-Q-ity, Inc. (Inactive) Company Overview
  • 5.80. OPKO Health, Inc. Company Overview
  • 5.81. Orion Genomics LLC Company Overview
  • 5.82. OTraces Inc. Company Overview
  • 5.83. Oxford Gene Technology Limited Company Overview
  • 5.84. PeriRx LLC Company Overview
  • 5.85. PleX Diagnostics Company Overview
  • 5.86. Precision Biologics, Inc. Company Overview
  • 5.87. PreMD Inc. Company Overview
  • 5.88. Proplex Technologies, Llc Company Overview
  • 5.89. Proteome Sciences Plc Company Overview
  • 5.90. Proteomika Company Overview
  • 5.91. Quest Diagnostics Incorporated Company Overview
  • 5.92. RCP Diagnostics, LLC (Inactive) Company Overview
  • 5.93. RiboMed Biotechnologies, Inc. Company Overview
  • 5.94. Roche Diagnostics International Ltd. Company Overview
  • 5.95. Rosetta Genomics, Ltd. Company Overview
  • 5.96. Roswell Park Cancer Institute Company Overview
  • 5.97. Siemens Healthcare Diagnostics Inc. Company Overview
  • 5.98. Sienna Cancer Diagnostics Ltd Company Overview
  • 5.99. Sividon Diagnostics GmbH Company Overview
  • 5.100. SomaLogic, Inc. Company Overview
  • 5.101. Southern Illinois University Carbondale Company Overview
  • 5.102. Syndax Pharmaceuticals, Inc. Company Overview
  • 5.103. The Wistar Institute Company Overview
  • 5.104. Todos Medical Company Overview
  • 5.105. Transgene SA Company Overview
  • 5.106. Trinity College Dublin Company Overview
  • 5.107. University of Chicago Company Overview
  • 5.108. University of Colorado Company Overview
  • 5.109. University of South Florida Company Overview
  • 5.110. University of Strathclyde Company Overview
  • 5.111. US Biomarkers, Inc. Company Overview
  • 5.112. Ventana Medical Systems, Inc. Company Overview
  • 5.113. Veracyte, Inc. Company Overview
  • 5.114. Vigilant Biosciences, Inc. Company Overview
  • 5.115. Viomics Inc. Company Overview
  • 5.116. VisionGate, Inc. Company Overview
  • 5.117. Vitatex Inc. Company Overview
  • 5.118. VolitionRX Ltd. Company Overview
  • 5.119. XEPTAGEN SpA Company Overview
  • 5.120. Zetiq Technologies Ltd. Company Overview

6. Lung Cancer- Recent Developments

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Lung Cancer - Pipeline Products by Stage of Development
  • Table 2: Lung Cancer - Pipeline Products by Territory
  • Table 3: Lung Cancer - Pipeline Products by Regulatory Path
  • Table 4: Lung Cancer - Pipeline Products by Estimated Approval Date
  • Table 5: Lung Cancer - Ongoing Clinical Trials
  • Table 6: Lung Cancer Companies - Pipeline Products by Stage of Development
  • Table 7: Lung Cancer - Pipeline Products by Stage of Development
  • Table 8: A&G Pharmaceutical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: Onco 88 - Lung Cancer - Product Status
  • Table 10: Onco 88 - Lung Cancer - Product Description
  • Table 11: OncoStain 88 - Lung Cancer - Product Status
  • Table 12: OncoStain 88 - Lung Cancer - Product Description
  • Table 13: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
  • Table 14: ACTN4 Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 15: ACTN4 Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 16: ALK Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 17: ALK Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 18: cMET Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 19: cMET Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 20: EML4 Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 21: EML4 Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 22: FGFR1 Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 23: FGFR1 Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 24: Heregulin Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 25: Heregulin Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 26: IGF1R Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 27: IGF1R Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 28: MAGE-A3 Companion Lung Cancer Assay - Product Status
  • Table 29: MAGE-A3 Companion Lung Cancer Assay - Product Description
  • Table 30: PIK3CA Companion Diagnostic Assay - Lung Cancer - Product Status
  • Table 31: PIK3CA Companion Diagnostic Assay - Lung Cancer - Product Description
  • Table 32: PRAME Antigen Lung Cancer Assay - Product Status
  • Table 33: PRAME Antigen Lung Cancer Assay - Product Description
  • Table 34: Abcodia Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 35: Diagnostic Assay - Lung Cancer - Product Status
  • Table 36: Diagnostic Assay - Lung Cancer - Product Description
  • Table 37: Aberystwyth University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 38: Diagnostic Biomarker Test - Lung Cancer - Product Status
  • Table 39: Diagnostic Biomarker Test - Lung Cancer - Product Description
  • Table 40: Advanced Marker Discovery, S.L. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 41: Predictive Diagnostic Test - Lung Cancer - Product Status
  • Table 42: Predictive Diagnostic Test - Lung Cancer - Product Description
  • Table 43: Prognostic Test - Lung Cancer - Product Status
  • Table 44: Prognostic Test - Lung Cancer - Product Description
  • Table 45: Advpharma Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 46: Lung Cancer Prognostic Assay - Product Status
  • Table 47: Lung Cancer Prognostic Assay - Product Description
  • Table 48: Molecular Diagnostic Biomarker - Lung Cancer - Product Status
  • Table 49: Molecular Diagnostic Biomarker - Lung Cancer - Product Description
  • Table 50: Almac Diagnostics Limited Pipeline Products & Ongoing Clinical Trials Overview
  • Table 51: Prognostic Test - Early Stage Lung Cancer - Product Status
  • Table 52: Prognostic Test - Early Stage Lung Cancer - Product Description
  • Table 53: Armune BioScience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 54: Diagnostic Test - Lung Cancer - Product Status
  • Table 55: Diagnostic Test - Lung Cancer - Product Description
  • Table 56: Aurelium BioPharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 57: Lung Cancer Screening Test - Product Status
  • Table 58: Lung Cancer Screening Test - Product Description
  • Table 59: Biocept, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 60: MicroRNA Test - Lung Cancer - Product Status
  • Table 61: MicroRNA Test - Lung Cancer - Product Description
  • Table 62: Biodesix Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 63: TAm-Seq NGS Lung Cancer Test - Product Status
  • Table 64: TAm-Seq NGS Lung Cancer Test - Product Description
  • Table 65: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 66: Metabolomics-based Diagnostic Assay - Lung Cancer - Product Status
  • Table 67: Metabolomics-based Diagnostic Assay - Lung Cancer - Product Description
  • Table 68: BioMark Diagnostics Inc. - Ongoing Clinical Trials Overview
  • Table 69: Metabolomics-based Diagnostic Assay - Lung Cancer - Clinical Trial with Patented Non-invasive, Urine-based Assay to Measure Response to Treatment for Lung Cancer
  • Table 70: BioMark Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 71: Biomarker Assay - Lung Cancer - Product Status
  • Table 72: Biomarker Assay - Lung Cancer - Product Description
  • Table 73: BioMarker Strategies, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 74: Ex Vivo Biomarker Test - Lung Cancer - Product Status
  • Table 75: Ex Vivo Biomarker Test - Lung Cancer - Product Description
  • Table 76: Biomoda, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 77: CyPath Diagnostic Assay - Lung Cancer - Product Status
  • Table 78: CyPath Diagnostic Assay - Lung Cancer - Product Description
  • Table 79: Biomoda, Inc. (Inactive) - Ongoing Clinical Trials Overview
  • Table 80: CyPath Diagnostic Assay - Lung Cancer - Evaluation of The Biomoda CyPath Early Lung Cancer Detection Assay
  • Table 81: CyPath Diagnostic Assay - Lung Cancer - Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
  • Table 82: BioNTech AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 83: Lung Cancer Screening Test - Product Status
  • Table 84: Lung Cancer Screening Test - Product Description
  • Table 85: BioSystems International Pipeline Products & Ongoing Clinical Trials Overview
  • Table 86: Diagnostic Test - Lung Cancer - Product Status
  • Table 87: Diagnostic Test - Lung Cancer - Product Description
  • Table 88: BioTime, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 89: PanC-Dx - Lung Cancer - Product Status
  • Table 90: PanC-Dx - Lung Cancer - Product Description
  • Table 91: Boise State University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 92: Micro-RNA Based Diagnostic Test - Lung Cancer - Product Status
  • Table 93: Micro-RNA Based Diagnostic Test - Lung Cancer - Product Description
  • Table 94: Cancer Research Technology Limited Pipeline Products & Ongoing Clinical Trials Overview
  • Table 95: Biomarker Test - Lung Cancer - Product Status
  • Table 96: Biomarker Test - Lung Cancer - Product Description
  • Table 97: Cangen Biotechnologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 98: Diagnostic Test - Early Stage Lung Cancer - Product Status
  • Table 99: Diagnostic Test - Early Stage Lung Cancer - Product Description
  • Table 100: Cangen Biotechnologies, Inc. - Ongoing Clinical Trials Overview
  • Table 101: Diagnostic Test - Early Stage Lung Cancer - Development Of An Early Stage Lung Cancer Diagnostic
  • Table 102: Celera Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 103: Lung Cancer Genotyping Assay - Product Status
  • Table 104: Lung Cancer Genotyping Assay - Product Description
  • Table 105: Cellanyx Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 106: Cellanyx Test - Lung Cancer - Product Status
  • Table 107: Cellanyx Test - Lung Cancer - Product Description
  • Table 108: CellMax Life Pipeline Products & Ongoing Clinical Trials Overview
  • Table 109: Diagnostic Assay - Lung Cancer - Product Status
  • Table 110: Diagnostic Assay - Lung Cancer - Product Description
  • Table 111: CeMines, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 112: CellCorrect LAb Test For Lung Cancer - Product Status
  • Table 113: CellCorrect LAb Test For Lung Cancer - Product Description
  • Table 114: Cepheid Pipeline Products & Ongoing Clinical Trials Overview
  • Table 115: Xpert OncoScreen Lung Cancer Assay - Product Status
  • Table 116: Xpert OncoScreen Lung Cancer Assay - Product Description
  • Table 117: Ceres Nanosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 118: Nanotrap Lung Cancer Biomarker Test - Product Status
  • Table 119: Nanotrap Lung Cancer Biomarker Test - Product Description
  • Table 120: Cernostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 121: TissueCypher Lung Cancer Test - Product Status
  • Table 122: TissueCypher Lung Cancer Test - Product Description
  • Table 123: ChemImage Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 124: Prognostic Test - Lung Cancer - Product Status

List of Figures

  • Figure 1: Lung Cancer - Pipeline Products by Stage of Development
  • Figure 2: Lung Cancer - Pipeline Products by Territory
  • Figure 3: Lung Cancer - Pipeline Products by Regulatory Path
  • Figure 4: Lung Cancer - Pipeline Products by Estimated Approval Date
  • Figure 5: Lung Cancer - Ongoing Clinical Trials
Back to Top